Physician profile
Robert J Albin
NPI 1619057668
$2,593.14
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $658 · 2021: $639 · 2022: $106 · 2024: $31.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $558.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $385.92 | 2019-2021 | |
| Harmony Biosciences LLC | $325.38 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.86 | 2019-2022 | |
| Monaghan Medical Corporation | $150.00 | 2019 | |
| Grifols USA, LLC | $126.35 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $123.94 | 2019-2021 | |
| Mylan Specialty L.P. | $113.21 | 2019-2022 | |
| Fisher & Paykel Healthcare INC | $88.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $60.07 | 2019 | |
| Advanced Respiratory, INC | $51.31 | 2019 | |
| Insmed, INC. | $47.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.40 | 2019 | |
| Boston Scientific Corporation | $31.63 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.86 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $27.93 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $26.59 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.06 | 2020 | |
| Electromed, INC. | $21.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.16 | 2019 | |
| Abbvie INC. | $12.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Albin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.